Literature DB >> 15947271

Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas.

Robert G Hart1, Silvina B Tonarelli, Lesly A Pearce.   

Abstract

BACKGROUND: Approximately 7000 intracerebral hemorrhages (ICHs) annually in the US are caused by use of antithrombotic therapies. We review the incidence, risk factors, and predictors of ICH in patients receiving long-term anticoagulation or antiplatelet therapy. SUMMARY OF REVIEW: ICH rates range from 0.3% to 0.6% per year during oral anticoagulation in recent reports. Major risk factors are advanced patient age, elevated blood pressure, intensity of anticoagulation, and previous cerebral ischemia. Combining antiplatelet agents with anticoagulation and the combined use of aspirin plus clopidogrel appear to increase ICH risk. Modest blood pressure-lowering halves the frequency of ICH during antiplatelet therapy.
CONCLUSIONS: ICH is an uncommon, but often fatal, complication of antithrombotic therapy that particularly afflicts patients with previous stroke. Recent data support that keeping international normalized ratio < or =3.0, control of hypertension, and avoiding the combination of aspirin with warfarin reduce its frequency.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15947271     DOI: 10.1161/01.STR.0000170642.39876.f2

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  67 in total

Review 1.  Comparison of published explicit criteria for potentially inappropriate medications in older adults.

Authors:  Chirn-Bin Chang; Ding-Cheng Chan
Journal:  Drugs Aging       Date:  2010-12-01       Impact factor: 3.923

2.  Death and disability from warfarin-associated intracranial and extracranial hemorrhages.

Authors:  Margaret C Fang; Alan S Go; Yuchiao Chang; Elaine M Hylek; Lori E Henault; Nancy G Jensvold; Daniel E Singer
Journal:  Am J Med       Date:  2007-05-24       Impact factor: 4.965

Review 3.  Antithrombotic treatment in atrial fibrillation.

Authors:  L Kalra; G Y H Lip
Journal:  Heart       Date:  2006-09-04       Impact factor: 5.994

Review 4.  [Anticoagulation for stroke prevention. An update].

Authors:  H C Koennecke
Journal:  Nervenarzt       Date:  2007-10       Impact factor: 1.214

5.  INTERMACS Analysis of Stroke During Support With Continuous-Flow Left Ventricular Assist Devices: Risk Factors and Outcomes.

Authors:  Deepak Acharya; Renzo Loyaga-Rendon; Charity J Morgan; Kara A Sands; Salpy V Pamboukian; Indranee Rajapreyar; William L Holman; James K Kirklin; José A Tallaj
Journal:  JACC Heart Fail       Date:  2017-10       Impact factor: 12.035

Review 6.  Treatment targets in intracerebral hemorrhage.

Authors:  Navdeep Sangha; Nicole R Gonzales
Journal:  Neurotherapeutics       Date:  2011-07       Impact factor: 7.620

7.  Determinants of intracranial hemorrhage incidence in patients on oral anticoagulation followed at the Lahey clinic.

Authors:  Simon Mantha; Ann Marie Pianka; Nicholas Tsapatsaris
Journal:  J Thromb Thrombolysis       Date:  2011-10       Impact factor: 2.300

Review 8.  [Treatment and care strategies for Alzheimer's disease and related dementias].

Authors:  H Förstl
Journal:  Nervenarzt       Date:  2008-05       Impact factor: 1.214

Review 9.  Warfarin-associated intracerebral hemorrhage.

Authors:  Anna Cavallini; Simona Fanucchi; Alessandra Persico
Journal:  Neurol Sci       Date:  2008-09       Impact factor: 3.307

Review 10.  Assessing bleeding risk in patients taking anticoagulants.

Authors:  Marwa Shoeb; Margaret C Fang
Journal:  J Thromb Thrombolysis       Date:  2013-04       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.